Virax Biolabs Group (VRAX) Competitors $1.94 +0.06 (+3.19%) (As of 03:00 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends VRAX vs. CLDI, XCUR, BTAI, CVKD, LSTA, CMMB, TPST, PULM, FBRX, and COCPShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Calidi Biotherapeutics (CLDI), Exicure (XCUR), BioXcel Therapeutics (BTAI), Cadrenal Therapeutics (CVKD), Lisata Therapeutics (LSTA), Chemomab Therapeutics (CMMB), Tempest Therapeutics (TPST), Pulmatrix (PULM), Forte Biosciences (FBRX), and Cocrystal Pharma (COCP). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Calidi Biotherapeutics Exicure BioXcel Therapeutics Cadrenal Therapeutics Lisata Therapeutics Chemomab Therapeutics Tempest Therapeutics Pulmatrix Forte Biosciences Cocrystal Pharma Calidi Biotherapeutics (NYSE:CLDI) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings. Which has stronger valuation & earnings, CLDI or VRAX? Virax Biolabs Group has higher revenue and earnings than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalidi Biotherapeutics$50K495.51-$29.22MN/AN/AVirax Biolabs Group$160K39.16-$6.73MN/AN/A Does the MarketBeat Community believe in CLDI or VRAX? Calidi Biotherapeutics and Virax Biolabs Group both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformCalidi BiotherapeuticsN/AN/AVirax Biolabs GroupN/AN/A Does the media favor CLDI or VRAX? In the previous week, Calidi Biotherapeutics had 7 more articles in the media than Virax Biolabs Group. MarketBeat recorded 7 mentions for Calidi Biotherapeutics and 0 mentions for Virax Biolabs Group. Calidi Biotherapeutics' average media sentiment score of 0.31 beat Virax Biolabs Group's score of 0.00 indicating that Calidi Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Calidi Biotherapeutics Neutral Virax Biolabs Group Neutral Is CLDI or VRAX more profitable? Company Net Margins Return on Equity Return on Assets Calidi BiotherapeuticsN/A N/A -344.45% Virax Biolabs Group N/A N/A N/A Do analysts prefer CLDI or VRAX? Calidi Biotherapeutics currently has a consensus target price of $16.67, suggesting a potential upside of 647.38%. Given Calidi Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Calidi Biotherapeutics is more favorable than Virax Biolabs Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals have more ownership in CLDI or VRAX? 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 24.3% of Calidi Biotherapeutics shares are owned by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, CLDI or VRAX? Calidi Biotherapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500. SummaryCalidi Biotherapeutics beats Virax Biolabs Group on 7 of the 12 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.27M$2.23B$5.10B$8.84BDividend YieldN/A0.75%5.04%4.07%P/E RatioN/A3.9395.6214.26Price / Sales39.1641.921,217.1987.73Price / CashN/A14.8239.5936.27Price / Book0.973.106.946.36Net Income-$6.73M$29.98M$118.89M$225.56M7 Day Performance2.11%-1.14%-1.33%-0.10%1 Month Performance19.02%-9.85%-3.17%2.02%1 Year Performance-16.74%-15.04%32.49%27.87% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group0.2701 of 5 stars$1.94+3.2%N/A-24.8%$6.27M$160,000.000.005CLDICalidi Biotherapeutics2.5503 of 5 stars$2.23-2.6%$16.67+647.4%N/A$24.78M$50,000.000.0041Gap DownHigh Trading VolumeXCURExicure1.8055 of 5 stars$11.38+1.7%N/A+1,914.4%$24.70M$28.83M-4.9550News CoverageGap DownTrading HaltedBTAIBioXcel Therapeutics4.5363 of 5 stars$0.58-2.2%$5.00+769.4%-84.6%$24.59M$1.38M0.0090Gap DownCVKDCadrenal Therapeutics1.6952 of 5 stars$14.79+2.0%$18.00+21.7%N/A$24.55MN/A0.004LSTALisata Therapeutics3.3126 of 5 stars$2.82-3.8%$15.00+431.9%+33.6%$23.66MN/A-1.1730Analyst ForecastCMMBChemomab Therapeutics2.8811 of 5 stars$1.58-3.6%$7.33+363.8%+228.0%$22.70MN/A0.0020TPSTTempest Therapeutics2.265 of 5 stars$0.89-0.5%$20.00+2,137.9%-76.2%$22.53MN/A-0.5920Analyst RevisionPULMPulmatrix0.2614 of 5 stars$6.15+9.4%N/A+210.5%$22.45M$7.30M-2.2820Analyst ForecastGap UpFBRXForte Biosciences3.6486 of 5 stars$15.35+13.3%$23.58+53.6%+69,372.9%$22.41MN/A-0.685Analyst RevisionNews CoverageGap DownHigh Trading VolumeCOCPCocrystal Pharma3.0541 of 5 stars$2.19+6.3%$7.00+219.6%+25.6%$22.27MN/A-1.1710 Related Companies and Tools Related Companies Calidi Biotherapeutics Competitors Exicure Competitors BioXcel Therapeutics Competitors Cadrenal Therapeutics Competitors Lisata Therapeutics Competitors Chemomab Therapeutics Competitors Tempest Therapeutics Competitors Pulmatrix Competitors Forte Biosciences Competitors Cocrystal Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VRAX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRAX Stock Alerts